Samaritan says research collaborator receives additional patent

New York, June 26 - Samaritan Pharmaceuticals Inc. said that the U.S. Patent Office has notified it of the issuance of patent No. 7,056,694 to Georgetown University, Samaritan's research collaborator.

The patent identifies peripheral-type benzodiazepine receptor associated proteins, such as PAP7, and their ability to interact with and regulate the function of the peripheral-type benzodiazepine receptor, a key mitochondrial protein involved in steroid biosynthesis, cell proliferation, cancer progression and Alzheimer's disease pathology.

Samaritan has an exclusive worldwide license.

Samaritan is a Las Vegas-based biotech company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.